Vaccines against tuberculosis: Where are we and where do we need to go?

PLoS Pathogens

Volumn 8, Issue 5, 2012, Pages

  Ottenhoff, Tom H M ^a   Kaufmann, Stefan H E ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B7 ANTIGEN; BCG VACCINE; CD137 ANTIGEN; CD27 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 22; INTERLEUKIN 23; LIVE VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; APOPTOSIS; AUTOPHAGY; BACTERIAL TRANSMISSION; BCG VACCINATION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EVALUATION; CLINICAL IMMUNOLOGY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; INFECTION CONTROL; INTERFERON GAMMA RELEASE ASSAY; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MIXED INFECTION; MYCOBACTERIUM BOVIS; NEUTROPHIL; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUBERCULIN TEST; TUBERCULOSIS; CD8+ T LYMPHOCYTE; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY;

CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG DESIGN; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84863690353     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002607     Document Type: Review

References (145)

1. Ottenhoff TH, (2009) Overcoming the global crisis: "yes, we can", but also for TB...? Eur J Immunol 39: 2014-2020.
2. Kaufmann SH, Winau F, (2005) From bacteriology to immunology: the dualism of specificity. Nat Immunol 6: 1063-1066.
3. Kaufmann SH, Hussey G, Lambert PH, (2010) New vaccines for tuberculosis. Lancet 375: 2110-2119.
4. WHO (2009) Global tuberculosis control: epidemiology, strategy, financing, WHO report 2009.
5. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.
6. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran. Chest 136: 420-425.
7. Calmette A, Guérin C, Boquet A, Négre L, (1927) La vaccination préventive contre la tuberculose par le "BCG". Masson.
8. Waksman SA, (1964) The conquest of tuberculosis University of California Press.
9. Kaufmann SH, Parida SK, (2007) Changing funding patterns in tuberculosis. Nat Med 13: 299-303.
10. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
11. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, et al. (2004) Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA 291: 2086-2091.
12. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PE, et al. (2007) The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 25: 14-18.
13. Ottenhoff TH, Verreck FA, Lichtenauer-Kaligis EG, Hoeve MA, Sanal O, et al. (2002) Genetics, cytokines and human infectious disease: lessons from weakly pathogenic mycobacteria and salmonellae. Nat Genet 32: 97-105.
14. Vosse Evd, Hoeve MA, Ottenhoff TH, (2004) Human genetics of intracellular infectious diseases: molecular and cellular immunity against mycobacteria and salmonellae. Lancet Infect Dis 4: 739-749.
15. Weir RE, Black GF, Nazareth B, Floyd S, Stenson S, et al. (2006) The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guerin vaccination in southern England and northern Malawi. Clin Exp Immunol 146: 390-399.
16. Barry CE III, Boshoff HI, Dartois V, Dick T, Ehrt S, et al. (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
17. Cobat A, Gallant CJ, Simkin L, Black GF, Stanley K, et al. (2009) Two loci control tuberculin skin test reactivity in an area hyperendemic for tuberculosis. J Exp Med 206: 2583-2591.
18. Rose DN, Schechter CB, Adler JJ, (1995) Interpretation of the tuberculin skin test. J Gen Intern Med 10: 635-642.
19. Lillebaek T, Andersen AB, Dirksen A, Smith E, Skovgaard LT, et al. (2002) Persistent high incidence of tuberculosis in immigrants in a low-incidence country. Emerg Infect Dis 8: 679-684.
20. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, et al. (2003) The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163: 1009-1021.
21. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098-104.
22. Pai M, Minion J, Steingart K, Ramsay A, (2010) New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 16: 271-284.
23. Parida SK, Kaufmann SH, (2010) The quest for biomarkers in tuberculosis. Drug Discov Today 15: 148-157.
24. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, et al. (2007) Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 104: 12434-12439.
25. Kaufmann SH, (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33: 567-577.
26. Stop TB Partnership Working Group on New TB Vaccines 2 (2010) The global plan to stop TB 2011-2015. Stop TB Partnership.
27. Liang Y, Wu X, Zhang J, Yang Y, Wang L, et al. (2011) Treatment of multi-drug-resistant tuberculosis in mice with DNA vaccines alone or in combination with chemotherapeutic drugs. Scand J Immunol 74: 42-46.
28. Andersen P, Doherty TM, (2005) The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol 3: 656-62.
29. Hatherill M, Adams V, Hughes J, de KM, Mavakla W, et al. (2009) The potential impact of helminth infection on trials of novel tuberculosis vaccines. Vaccine 27: 4743-4744.
30. Potian JA, Rafi W, Bhatt K, McBride A, Gause WC, et al. (2011) Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J Exp Med 208: 1863-1874.
31. Urdahl KB, Shafiani S, Ernst JD, (2011) Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol 4: 288-293.
32. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, et al. (2008) Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J Exp Med 205: 105-115.
33. Reiley WW, Calayag MD, Wittmer ST, Huntington JL, Pearl JE, et al. (2008) ESAT-6-specific CD4 T cell responses to aerosol Mycobacterium tuberculosis infection are initiated in the mediastinal lymph nodes. Proc Natl Acad Sci U S A 105: 10961-10966.
34. Gallegos AM, Pamer EG, Glickman MS, (2008) Delayed protection by ESAT-6-specific effector CD4+ T cells after airborne M. tuberculosis infection. J Exp Med 205: 2359-2368.
35. Ulrichs T, Kaufmann SH, (2006) New insights into the function of granulomas in human tuberculosis. J Pathol 208: 261-269.
36. Day TA, Koch M, Nouailles G, Jacobsen M, Kosmiadi GA, et al. (2010) Secondary lymphoid organs are dispensable for the development of T-cell-mediated immunity during tuberculosis. Eur J Immunol 40: 1663-1673.
37. Khader SA, Partida-Sanchez S, Bell G, Jelley-Gibbs DM, Swain S, et al. (2006) Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 203: 1805-1815.
38. Reece ST, Kaufmann SH, (2012) Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol 15: 63-70.
39. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, et al. (2004) Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119: 753-766.
40. Deretic V, (2006) Autophagy as an immune defense mechanism. Curr Opin Immunol 18: 375-382.
41. Rohde K, Yates RM, Purdy GE, Russell DG, (2007) Mycobacterium tuberculosis and the environment within the phagosome. Immunol Rev 219: 37-54.
42. Sahiratmadja E, Alisjahbana B, de BT, Adnan I, Maya A, et al. (2007) Dynamic changes in pro- and anti-inflammatory cytokine profiles and gamma interferon receptor signaling integrity correlate with tuberculosis disease activity and response to curative treatment. Infect Immun 75: 820-829.
43. van der Wel N, Hava D, Houben D, Fluitsma D, van ZM, et al. (2007) M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129: 1287-1298.
44. Dorhoi A, Reece ST, Kaufmann SH, (2011) For better or for worse: the immune response against Mycobacterium tuberculosis balances pathology and protection. Immunol Rev 240: 235-251.
45. Casanova JL, Abel L, (2002) Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20: 581-620.
46. Ottenhoff TH, Neuteboom S, Elferink DG, de Vries RR, (1986) Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients. J Exp Med 164: 1923-1939.
47. Geluk A, Bloemhoff W, de Vries RR, Ottenhoff TH, (1992) Binding of a major T cell epitope of mycobacteria to a specific pocket within HLA-DRw17(DR3) molecules. Eur J Immunol 22: 107-113.
48. Ladel CH, Daugelat S, Kaufmann SH, (1995) Immune response to Mycobacterium bovis bacille Calmette Guerin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance. Eur J Immunol 25: 377-384.
49. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, et al. (2011) Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 34: 807-819.
50. Sallusto F, Lanzavecchia A, (2009) Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur J Immunol 39: 2076-2082.
51. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
52. Cooper AM, (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27: 393-422.
53. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
54. Okamoto YY, Umemura M, Yahagi A, O'Brien RL, Ikuta K, et al. (2010) Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184: 4414-4422.
55. Cruz A, Fraga AG, Fountain JJ, Rangel-Moreno J, Torrado E, et al. (2010) Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med 207: 1609-1616.
56. Torrado E, Robinson RT, Cooper AM, (2011) Cellular response to mycobacteria: balancing protection and pathology. Trends Immunol 32: 66-72.
57. Ottenhoff TH, Lewinsohn DA, Lewinsohn DM, (2008) Human CD4 and CD8 T cell responses to Mycobacterium tuberculosis: antigen specificity, function, implications and applications. Handbook of tuberculosis. Immunology and cell biology Weinheim, Germany Wiley-VCH Verlag GmbH & Co.KGaA pp. 119-156.
58. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, et al. (2003) Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9: 1039-1046.
59. Winau F, Weber S, Sad S, de DJ, Hoops SL, et al. (2006) Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105-117.
60. Levine B, Mizushima N, Virgin HW, (2011) Autophagy in immunity and inflammation. Nature 469: 323-335.
61. Deretic V, (2010) Autophagy in infection. Curr Opin Cell Biol 22: 252-262.
62. Rolph MS, Raupach B, Kobernick HH, Collins HL, Perarnau B, et al. (2001) MHC class Ia-restricted T cells partially account for beta2-microglobulin-dependent resistance to Mycobacterium tuberculosis. Eur J Immunol 31: 1944-1949.
63. Schaible UE, Collins HL, Priem F, Kaufmann SH, (2002) Correction of the iron overload defect in beta-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 196: 1507-1513.
64. Joosten SA, van Meijgaarden KE, van Weeren PC, Kazi F, Geluk A, et al. (2010) Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog 6: e1000782 doi:10.1371/journal.ppat.1000782.
65. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, et al. (2002) HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells. J Exp Med 196: 1473-1481.
66. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, et al. (2010) Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8: e1000407 doi:10.1371/journal.pbio.1000407.
67. Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, et al. (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356: 2133-2138.
68. Keane J, Remold HG, Kornfeld H, (2000) Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J Immunol 164: 2016-2020.
69. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, et al. (1998) An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282: 121-125.
70. Caccamo N, Meraviglia S, La MC, Guggino G, Dieli F, et al. (2006) Phenotypical and functional analysis of memory and effector human CD8 T cells specific for mycobacterial antigens. J Immunol 177: 1780-1785.
71. Tang H, Pang S, Wang M, Xiao X, Rong Y, et al. (2010) TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. J Immunol 185: 2563-2569.
72. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, et al. (2010) Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am J Respir Crit Care Med 182: 1073-1079.
73. Gaseitsiwe S, Valentini D, Mahdavifar S, Reilly M, Ehrnst A, et al. (2010) Peptide microarray-based identification of Mycobacterium tuberculosis epitope binding to HLA-DRB1*0101, DRB1*1501, and DRB1*0401. Clin Vaccine Immunol 17: 168-175.
74. Lewinsohn DA, Winata E, Swarbrick GM, Tanner KE, Cook MS, et al. (2007) Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B. PLoS Pathog 3: e127 doi:10.1371/journal.ppat.0030127.
75. Commandeur S, van Meijgaarden KE, Lin MY, Franken KL, Friggen AH, et al. (2011) Identification of human T-cell responses to Mycobacterium tuberculosis resuscitation-promoting factors in long-term latently infected individuals. Clin Vaccine Immunol 18: 676-683.
76. Maglione PJ, Chan J, (2009) How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol 39: 676-686.
77. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, et al. (2010) An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466: 973-977.
78. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, et al. (2011) Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun 12: 15-22.
79. Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di CP, et al. (2009) Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 4: e5528 doi:10.1371/journal.pone.0005528.
80. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
81. Derrick SC, Yabe IM, Yang A, Morris SL, (2011) Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29: 2902-2909.
82. Sutherland JS, Adetifa IM, Hill PC, Adegbola RA, Ota MO, (2009) Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 39: 723-729.
83. Caccamo N, Guggino G, Joosten SA, Gelsomino G, Di CP, et al. (2010) Multifunctional CD4(+) T cells correlate with active Mycobacterium tuberculosis infection. Eur J Immunol 40: 2211-2220.
84. Smith SG, Lalor MK, Gorak-Stolinska P, Blitz R, Beveridge NE, et al. (2010) Mycobacterium tuberculosis PPD-induced immune biomarkers measurable in vitro following BCG vaccination of UK adolescents by multiplex bead array and intracellular cytokine staining. BMC Immunol 11: 35.
85. Young DB, Gideon HP, Wilkinson RJ, (2009) Eliminating latent tuberculosis. Trends Microbiol 17: 183-138.
86. Shafiani S, Tucker-Heard G, Kariyone A, Takatsu K, Urdahl KB, (2010) Pathogen-specific regulatory T cells delay the arrival of effector T cells in the lung during early tuberculosis. J Exp Med 207: 1409-1420.
87. Kursar M, Koch M, Mittrucker HW, Nouailles G, Bonhagen K, et al. (2007) Cutting Edge: Regulatory T cells prevent efficient clearance of Mycobacterium tuberculosis. J Immunol 178: 2661-2665.
88. Joosten SA, van Meijgaarden KE, Savage ND, de BT, Triebel F, et al. (2007) Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4. Proc Natl Acad Sci U S A 104: 8029-8034.
89. Joosten SA, Ottenhoff TH, (2008) Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol 69: 760-770.
90. Ottenhoff TH, Doherty TM, van Dissel JT, Bang P, Lingnau K, et al. (2010) First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum Vaccin 6: 1007-1015.
91. Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, et al. (2004) Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 190: 115-122.
92. Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, et al. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17: 1261-1268.
93. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA, (2008) A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG. Infect Immun 76: 5200-5214.
94. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, et al. (2008) A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198: 1491-1501.
95. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533-539.
96. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, et al. (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27: 4412-4423.
97. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, et al. (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
98. Decatur AL, Portnoy DA, (2000) A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity. Science 290: 992-995.
99. Palmer M, (2001) The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 39: 1681-1689.
100. Torchinsky MB, Garaude J, Martin AP, Blander JM, (2009) Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 458: 78-82.
101. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, et al. (2011) Recombinant BCG {Delta}ureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses. J Infect Dis 204: 1573-1584.
102. Mollenkopf HJ, Grode L, Mattow J, Stein M, Mann P, et al. (2004) Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis. Infect Immun 72: 6471-6479.
103. Kupferschmidt K, (2011) Infectious disease. Taking a new shot at a TB vaccine. Science 334: 1488-1490.
104. Guleria I, Teitelbaum R, McAdam RA, Kalpana G, Jacobs WR Jr, et al. (1996) Auxotrophic vaccines for tuberculosis. Nat Med 2: 334-337.
105. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006) Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320.
106. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, et al. (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24: 3408-3419.
107. Lee JS, Krause R, Schreiber J, Mollenkopf HJ, Kowall J, et al. (2008) Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microbe 3: 97-103.
108. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, et al. (2004) Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10: 1240-1244.
109. Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, et al. (2010) Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol 40: 279-290.
110. Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, et al. (2007) Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infect Immun 75: 4105-4115.
111. Abel B, Tameris M, Mansoor N, Gelderbloem S, Hughes J, et al. (2010) The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am J Respir Crit Care Med 181: 1407-1417.
112. Hutnick NA, Carnathan DG, Dubey SA, Makedonas G, Cox KS, et al. (2009) Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells. Nat Med 15: 876-878.
113. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, et al. (2010) Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16: 339-345.
114. van Dissel JT, Arend SM, Prins C, Bang P, Tingskov PN, et al. (2010) Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28: 3571-3581.
115. van Dissel JT, Soonawala D, Joosten SA, Prins C, Arend SM, et al. (2011) Ag85B-ESAT-6 adjuvanted with IC31(R) promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine 29: 2100-2109.
116. Von Eschen K, Morrison R, Braun M, Ofori-Anyinam O, De KE, et al. (2009) The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans. Hum Vaccin 5: 475-482.
117. Davidsen J, Rosenkrands I, Christensen D, Vangala A, Kirby D, et al. (2005) Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6′-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta 1718: 22-31.
118. Agger EM, Rosenkrands I, Hansen J, Brahimi K, Vandahl BS, et al. (2008) Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS ONE 3: e3116 doi:10.1371/journal.pone.0003116.
119. Ishikawa E, Ishikawa T, Morita YS, Toyonaga K, Yamada H, et al. (2009) Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med 206: 2879-2888.
120. Rouanet C, Debrie AS, Lecher S, Locht C, (2009) Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11: 995-1001.
121. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F, (2006) Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis (Edinb) 86: 303-309.
122. Pethe K, Alonso S, Biet F, Delogu G, Brennan MJ, et al. (2001) The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination. Nature 412: 190-194.
123. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, et al. (2003) Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment. J Exp Med 198: 693-704.
124. Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, et al. (2006) Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis. Microbes Infect 8: 2052-2060.
125. Black GF, Thiel BA, Ota MO, Parida SK, Adegbola R, et al. (2009) Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 16: 1203-1212.
126. Schuck SD, Mueller H, Kunitz F, Neher A, Hoffmann H, et al. (2009) Identification of T-cell antigens specific for latent mycobacterium tuberculosis infection. PLoS ONE 4: e5590 doi:10.1371/journal.pone.0005590.
127. Lin MY, Ottenhoff TH, (2008) Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Biol Chem 389: 497-511.
128. Lin MY, Ottenhoff TH, (2008) Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocr Metab Immune Disord Drug Targets 8: 15-29.
129. Rustad TR, Harrell MI, Liao R, Sherman DR, (2008) The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 3: e1502 doi:10.1371/journal.pone.0001502.
130. Aagaard C, Hoang T, Dietrich J, Cardona PJ, Izzo A, et al. (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17: 189-194.
131. Govender L, Abel B, Hughes EJ, Scriba TJ, Kagina BM, et al. (2010) Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease. Vaccine 29: 51-57.
132. Lin PL, Dietrich J, Tan E, Abalos RM, Burgos J, et al. (2012) The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. J Clin Invest 122: 303-314.
133. Wilson ME, Fineberg HV, Colditz GA, (1995) Geographic latitude and the efficacy of bacillus Calmette-Guerin vaccine. Clin Infect Dis 20: 982-991.
134. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, et al. (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770-1773.
135. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, et al. (2011) Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3: 104ra102.
136. Jacobsen M, Repsilber D, Kleinsteuber K, Gutschmidt A, Schommer-Leitner S, et al. (2011) Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosisTB patients. Clin Microbiol Infect 17: 1323-1331.
137. Lockhart E, Green AM, Flynn JL, (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177: 4662-4669.
138. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, et al. (2012) Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun 13: 71-82.
139. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, et al. (2010) Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
140. Schuurhuis DH, van MN, Ioan-Facsinay A, Jiawan R, Camps M, et al. (2006) Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 176: 4573-4580.
141. Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, et al. (2008) Immunization by a bacterial aerosol. Proc Natl Acad Sci U S A 105: 4656-4660.
142. Jeyanathan M, Heriazon A, Xing Z, (2010) Airway luminal T cells: a newcomer on the stage of TB vaccination strategies. Trends Immunol 31: 247-252.
143. Jeyanathan M, Mu J, McCormick S, Damjanovic D, Small CL, et al. (2010) Murine airway luminal antituberculosis memory CD8 T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. Am J Respir Crit Care Med 181: 862-872.
144. Tchilian EZ, Ronan EO, de Lara C, Lee LN, Franken KL, et al. (2011) Simultaneous immunization against tuberculosis. PLoS ONE 6: e27477 doi:10.1371/journal.pone.0027477.
145. Lee LN, Ronan EO, de LC, Franken KL, Ottenhoff TH, et al. (2011) CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun 79: 3328-3337.